BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 10857475)

  • 1. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug patent expirations and the speed of generic entry.
    Bae JP
    Health Serv Res; 1997 Apr; 32(1):87-101. PubMed ID: 9108806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting future drug expenditures--1993.
    Santell JP
    Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 14. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 17. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
    Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
    Mahlich JC; Stadler I
    Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.